Literature DB >> 7785662

Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.

D J Weissmann1, J A Ferry, N L Harris, D N Louis, F Delmonico, I Spiro.   

Abstract

Patients immunosuppressed after organ transplantation have an increased frequency of lymphoproliferative disorders, known as posttransplantation lymphoproliferative disorders (PTLDs). In recipients of bone marrow allografts. PTLDs are often of donor origin. In only a few cases of lymphoma arising in solid-organ transplant recipients has the origin from host or donor lymphocytes been established. The authors have analyzed 11 cases of PTLD from Massachusetts General Hospital, arising in seven male and four female patients, aged 8 to 63, five with renal, four with cardiac, and two with hepatic allografts. Using the polymerase chain reaction (PCR) to investigate genetic polymorphism at the D4S174 locus on chromosome 4, the Rb1.20 locus on chromosome 13, and the D19S178 locus on chromosome 19, only one tumor (previously reported) was of donor origin, whereas 10 were of host origin. Follow-up revealed that six patients died of PTLD, one was alive with recurrent PTLD, and four were alive and well or had died of other causes, including the patient with donor-origin PTLD. Based on these cases and on a review of previously reported cases, the authors conclude that the majority of PTLDs in solid organ recipients are of host origin. There appears to be a trend toward a greater likelihood of persistent or recurrent PTLD among solid organ recipients with host-origin tumors than among those with donor-origin tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785662     DOI: 10.1093/ajcp/103.6.748

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

1.  The mother lode of liver transplantation, with particular reference to our new journal.

Authors:  T E Starzl
Journal:  Liver Transpl Surg       Date:  1998-01

2.  Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.

Authors:  M A Nalesnik; A S Rao; A Zeevi; J J Fung; S Pham; H Furukawa; A Gritsch; G Klein; T E Starzl
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

3.  Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single center.

Authors:  Sule Mine Bakanay; Gülşah Kaygusuz; Pervin Topçuoğlu; Sule Sengül; Timur Tunçalı; Kenan Keven; Işınsu Kuzu; Akın Uysal; Mutlu Arat
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

4.  Hepatic involvement by lymphoproliferative disorders post liver transplantation: PTLD.Int. Survey.

Authors:  Morteza Izadi; Mozhgan Fazel; Seyed Hasan Saadat; Saeed Taheri
Journal:  Hepatol Int       Date:  2011-03-30       Impact factor: 6.047

Review 5.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 6.  Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD).

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.

Authors:  A Chadburn; N Suciu-Foca; E Cesarman; E Reed; R E Michler; D M Knowles
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

8.  Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease.

Authors:  J Setsuda; J Teruya-Feldstein; N L Harris; J A Ferry; L Sorbara; G Gupta; E S Jaffe; G Tosato
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 9.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14

10.  Techniques for ovarian tissue, whole ovary, oocyte and embryo cryopreservation.

Authors:  Ozmen Batuhan; Al-Hassani Safaa
Journal:  J Reprod Infertil       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.